Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hypoglycemic Agents Clear all
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Glargine U300 Hospital Trial

NCT03013985
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glargine U300, Glargine U100, Glulisine Insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

NCT02107976
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Vitamin E, Vitamin C
Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 19, 2026, 4:27 PM EDT
Completed No phase listed Observational

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

NCT04215536
View directory record Official record
Conditions
Diabetes
Interventions
Empagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
103,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control

NCT04016558
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Distress
Interventions
StreamLine, TunedIn, FixIt
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional

African American Children, Glycemic Control, and Type 2 Diabetes

NCT01325987
View directory record Official record
Conditions
Type 2 Diabetes, Vitamin D Deficiency
Interventions
Vitamin D2, Sugar pill
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

NCT00099333
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
5
States / cities
Chula Vista, California • Butte, Montana • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 19, 2026, 4:27 PM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 19, 2026, 4:27 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia

NCT02700048
View directory record Official record
Conditions
Hypoglycemia Unawareness, Type 1 Diabetes
Interventions
intra-nasal naloxone, Intra-nasal saline
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Integrating Depression Services Into DM Management

NCT01098253
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Depression
Interventions
Adherence Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

NCT02182895
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Saxagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hypoglycemic Clamp
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 19, 2026, 4:27 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
View directory record Official record
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 19, 2026, 4:27 PM EDT
Not listed Phase 1 Interventional

UVA Islet Cell Transplantation in Patients With Type I Diabetes

NCT00605592
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Pancreatic Islets of Langerhans Cell Transplant
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System

NCT01390259
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Open-Loop, Closed-Loop
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

NCT06046560
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes
Interventions
SGLT2 inhibitor, GLP-1 RA, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
27 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 19, 2026, 4:27 PM EDT
Completed No phase listed Observational

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

NCT05033054
View directory record Official record
Conditions
Kidney Disease, Chronic, Diabetes
Interventions
SGLT2 inhibitor
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 19, 2026, 4:27 PM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon

NCT02516150
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ethanol, Glucagon
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes

NCT06141941
View directory record Official record
Conditions
Pregestational Diabetes
Interventions
CGM
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CS-917, metformin hydrochloride, pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 19, 2026, 4:27 PM EDT